Study guide

21.3 Contrast Optimization: Mechanical Index, Destruction, Replenishment, and Artifacts

CCI Registered Cardiac Sonographer RCS

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: RCS Orientation and Clinical Context

1.1 RCS Identity, Exam Format, Application, and Retesting 1.2 Clinical History, Symptoms, Indications, and Risk Factors 1.3 Prior Studies, Serial Change, and Cross-Modality Context

2 Chapter 2: Orders, Safety, and Patient Preparation

2.1 Order Verification, Scope, and Protocol Selection 2.2 Sonographer Ergonomics and Staff Safety 2.3 Patient Preparation, Positioning, Consent, Infection Control, and Aftercare

3 Chapter 3: Reporting and 2-D TTE Foundations

3.1 Structured Findings, Significant Results, and Escalation 3.2 Standard 2-D TTE Windows, Views, and Acquisition Sequence 3.3 2-D Measurements, Foreshortening, Image Quality, and QA

4 Chapter 4: M-Mode and Doppler Acquisition

4.1 M-Mode Alignment, Timing, Measurements, and Pitfalls 4.2 Color Doppler Acquisition, Scale, Gain, and Jet Display 4.3 PW and CW Spectral Doppler Acquisition

5 Chapter 5: Advanced Doppler and Contrast

5.1 Tissue Doppler and Hemodynamic Sample Placement 5.2 Ultrasound-Enhancing Agents and LV Opacification 5.3 Agitated-Saline Studies and Intracardiac Shunts

6 Chapter 6: Stress Echocardiography

6.1 Exercise Stress Echo Protocols and Peak Imaging 6.2 Pharmacologic Stress Echo, Dobutamine, and Safety 6.3 Non-Ischemic Stress Echo and Hemodynamic Provocation

7 Chapter 7: TEE, Strain, and 3-D TEE

7.1 Assisting TEE: Preparation, Probe Safety, Views, and Complications 7.2 Strain Acquisition, Tracking Quality, and Reproducibility 7.3 3-D TEE Acquisition, Cropping, Orientation, and Artifacts

8 Chapter 8: 3-D TTE and the Aortic Valve

8.1 3-D TTE Full-Volume Acquisition and Quantitation 8.2 Aortic-Valve Anatomy, Morphology, and Function 8.3 Aortic Stenosis: Velocities, Gradients, Valve Area, and Flow States

9 Chapter 9: Aortic Regurgitation and Mitral Structure

9.1 Aortic Regurgitation Mechanisms and Integrated Severity 9.2 Mitral-Valve Anatomy, Motion, and Mechanisms 9.3 Mitral Stenosis: Planimetry, Gradients, Pressure Half-Time, and Suitability

10 Chapter 10: Mitral and Tricuspid Valve Findings

10.1 Mitral Regurgitation Mechanism, Quantitation, and Severity Integration 10.2 Tricuspid-Valve Anatomy, Structure, and Function 10.3 Tricuspid Stenosis Assessment

11 Chapter 11: Right-Sided Valve Disease

11.1 Tricuspid Regurgitation Mechanism and Severity 11.2 Pulmonic-Valve Anatomy, Structure, and Function 11.3 Pulmonic Stenosis Assessment

12 Chapter 12: Pulmonic Regurgitation and Prosthetic Valves

12.1 Pulmonic Regurgitation Mechanism and Severity 12.2 Normal Mechanical and Bioprosthetic Valve Assessment 12.3 Prosthetic Obstruction, Regurgitation, Thrombosis, and Patient–Prosthesis Mismatch

13 Chapter 13: Endocarditis and Cardiac Chambers

13.1 Valvular Endocarditis, Vegetations, Abscess, and Complications 13.2 LV and LA Size, Geometry, Volumes, Mass, and Function 13.3 RV and RA Size, Pressure, Volume, and Function

14 Chapter 14: Cardiomyopathy Phenotypes and Diastology

14.1 Dilated and Hypertrophic Cardiomyopathies, SAM, and LVOT Obstruction 14.2 Restrictive, Arrhythmogenic, and Stress Cardiomyopathies 14.3 Diastolic Function, Filling Pressure, Grading, and Pitfalls

15 Chapter 15: Systolic Function and Ischemia

15.1 LV Systolic Function, Simpson EF, Regional Motion, and Output 15.2 RV Systolic Function: TAPSE, S-prime, FAC, and Coupling 15.3 Ischemic Heart Disease, Coronary Territories, Stress Response, and Complications

16 Chapter 16: Pericardium and Great Vessels

16.1 Pericardial Effusion, Tamponade, Constriction, and Doppler Physiology 16.2 Great Vessels, Venous Return, and Pulmonary Artery Assessment 16.3 Aortic Root, Aneurysm, Dissection, and Coarctation

17 Chapter 17: Pulmonary Pressure, Masses, and Congenital Recognition

17.1 Pulmonary Hypertension, RAP/PASP Estimation, and RV Consequences 17.2 Cardiac Masses, Thrombus, Tumor, Vegetation, and Mimics 17.3 Adult Recognition of ASD, VSD, PFO, PDA, and Congenital Clues

18 Chapter 18: Devices, Strain, and Hemodynamics

18.1 ICDs, Pacemakers, Occluders, Closure Devices, and Mechanical Support 18.2 Strain Interpretation, Global Longitudinal Strain, and Disease Patterns 18.3 Cardiac Hemodynamics, Bernoulli, Continuity, Stroke Volume, and Shunts

19 Chapter 19: Infiltrative Disease and Physics Foundations

19.1 Amyloid, Sarcoid, and Other Infiltrative Disease Patterns 19.2 Ultrasound Wave Properties, Propagation, Frequency, and Wavelength 19.3 Artifact Recognition: Reverberation, Shadowing, Mirror, Refraction, and Aliasing

20 Chapter 20: Resolution and Doppler Optimization

20.1 Axial/Lateral Resolution, Frame Rate, Depth, Focus, and Trade-Offs 20.2 Spectral Doppler Optimization, Nyquist, Filters, Gain, and Angle 20.3 Color Doppler Optimization, Scale, Priority, Variance, and Gain

21 Chapter 21: 2-D, 3-D, and Contrast Optimization

21.1 2-D Optimization: Frequency, Gain, TGC, Harmonics, Depth, and Focus 21.2 3-D Optimization: Volume Rate, Stitching, Cropping, and Display 21.3 Contrast Optimization: Mechanical Index, Destruction, Replenishment, and Artifacts

21.3 Contrast Optimization: Mechanical Index, Destruction, Replenishment, and Artifacts

Key Takeaways Explain This Topic AI

Commercial intravenous UEAs are stable encapsulated microbubbles that traverse the pulmonary circulation for LV opacification; agitated saline primarily opacifies the right heart and tests abnormal right-to-left pathways.

Mechanical index is proportional to peak negative pressure divided by the square root of transmit frequency; very-low-MI contrast-specific imaging detects nonlinear bubble response while limiting routine destruction.

A brief high-MI flash intentionally destroys microbubbles, after which uniform replenishment can be observed; continuous intermediate/high MI instead causes unwanted destruction and swirling.

Optimize dose, delivery, MI, gain, focus, and depth to avoid near-field blooming, basal attenuation, apical destruction, swirling, and shadowing before calling thrombus, absent perfusion, or wall-motion abnormality.

Last updated: July 2026

Match the bubble to the clinical question

CCI task E9 is to optimize contrast imaging. A commercial ultrasound-enhancing agent (UEA) contains encapsulated high-molecular-weight gas microbubbles small and stable enough to traverse the pulmonary capillary bed after intravenous administration. Contrast-specific imaging detects their nonlinear acoustic response to opacify the LV cavity, improve endocardial borders and Doppler signals, and, under an authorized protocol, assess myocardial perfusion. UEA is recommended when two or more contiguous LV segments are inadequately seen for LV function or wall-motion assessment.

Agitated saline is a different test. Its larger, short-lived bubbles normally opacify the RA and RV but do not pass the pulmonary capillary bed. It is used with injection-site and provocative-maneuver protocols to evaluate intracardiac or intrapulmonary right-to-left passage and venous connections. Agitated saline does not replace commercial UEA for routine LV opacification; commercial UEA does not replace a properly performed agitated-saline shunt study. Label the agent, route, injection site, timing, and maneuver.

  • Question Preferred technique Key optimization
  • Inadequate LV border/EF Commercial UEA with LVO preset Homogeneous cavity, low/VLMI, no basal shadow
  • Stress wall motion UEA with low-destruction imaging Stable opacification and adequate frame rate
  • Myocardial perfusion VLMI plus authorized flash–replenishment Fixed plane, brief flash, observe uniform refill
  • Right-to-left shunt Agitated saline Dense RA opacification, correct injection and maneuver
  • Doppler enhancement Small UEA dose when indicated Avoid spectral overgain and blooming

Follow product labeling, local policy, trained-personnel scope, IV verification, dosing/delivery protocol, and monitoring requirements. Record the indication and any symptoms. Optimization never justifies improvising an unapproved preparation or bypassing a contraindication and emergency-response procedure.

Use mechanical index to control bubble behavior

Mechanical index is MI = peak rarefactional pressure / √transmit frequency in the system's standardized units. It is an index of acoustic output, not bubble dose. At very low MI, generally below 0.2 , microbubbles oscillate nonlinearly and contrast-specific multipulse sequences suppress linear tissue signal while preserving bubbles. This provides high bubble-to-tissue contrast for real-time LV opacification and perfusion. Raising output increases oscillation and eventually shell disruption, gas release, and loss of signal.

Continuous intermediate or high MI causes ongoing microbubble destruction, apical swirling, and heterogeneous cavity signal and should not be the default for LVO. Start with the manufacturer-specific LVO or VLMI preset, focus near or below the target, keep depth and sector only as large as needed, and use the lowest MI and gain that maintain uniform borders. Excess tissue gain defeats tissue cancellation; too little contrast gain or too low a dose leaves incomplete opacification.

For intentional destruction, use a brief high-MI “flash,” commonly several frames near MI 0.8–1.2 under the specified protocol, then immediately return to VLMI. The flash clears microbubbles from the myocardium; continued imaging shows replenishment from the microcirculation. A fixed plane, stable blood-pool concentration, ECG, and end-systolic comparison are important. Normal refill with 2-D imaging is generally uniform within about 5 seconds at rest and 2 seconds during stress, but perfusion interpretation requires specific training and authorization and must consider attenuation.

Balance delivery and instrument settings

A continuous diluted infusion can provide stable concentration; a small bolus with a slow saline flush can be effective for LVO. A rapid or excessive bolus produces dense near-field signal and acoustic shadowing of basal segments. Too little agent, infiltration, a poor IV, a fast destructive MI, or a long delay produces weak or swirling signal. Use product- and laboratory-specific preparation and dose rather than transferring volumes among agents. Wait for or restore a steady state before comparing views or replenishment.

Narrow the sector and reduce unnecessary depth to preserve frame rate, but include the entire myocardium. Place focus at or just below the structure per the contrast preset; a high focal pressure near the apex can increase local destruction. Adjust contrast gain so the cavity is homogeneous and tissue is suppressed without blooming the border into myocardium. Acquire nonforeshortened apical four-, two-, and long-axis views with the same plane held through destruction and refill.

Recognize concentration, energy, and propagation artifacts

Basal attenuation or shadowing occurs when a dense apical cavity absorbs/scatters energy, leaving basal segments dark. Reduce dose or concentration, slow the flush, use VLMI, change view, and allow concentration to fall. A defect that moves with the acoustic path or affects the far field more than a coronary distribution suggests attenuation.

Apical destruction and swirling occur when MI/focal pressure is too high or delivery is uneven. Lower MI, move focus deeper, use a slower flush or stable infusion, and wait for homogeneous mixing. Do not call apical thrombus from a transient dark swirl. Blooming from high contrast gain expands cavity signal across endocardium, hides trabeculae, and can make volumes too small; reduce gain and compare unenhanced anatomy.

Near-field rib/lung shadow, reverberation, side-lobe duplication, and tissue-suppression failure remain possible. A linear contrast echo outside the cavity may be artifact, not a dissection flap or shunt. Change window, frequency, depth, gain, MI, and harmonic/contrast-specific mode and confirm in another plane. During a flash, global signal loss is expected immediately; persistent regional delay is interpreted only after the blood pool has replenished and attenuation has been excluded.

UEA can reveal apical aneurysm, noncompaction recesses, pseudoaneurysm, or thrombus, but do not trace microbubble swirling as myocardium or mistake normal trabeculation for a mass. For a suspected thrombus, save precontrast and optimized postcontrast loops; a true avascular mass remains unopacified while the surrounding cavity fills, but artifact and low-flow stasis remain alternatives. The report states agent, administration method, MI/preset, image quality, views, adverse events, and whether enhancement resolved or merely narrowed the limitation.